NASDAQ:VYGR - Voyager Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $10.68 -0.21 (-1.93 %) (As of 02/22/2019 06:00 AM ET)Previous Close$10.89Today's Range$10.52 - $11.0052-Week Range$7.76 - $31.91Volume150,577 shsAverage Volume614,472 shsMarket Capitalization$347.74 millionP/E Ratio-4.05Dividend YieldN/ABeta2.58 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease. Its preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; Tau program, for tauopathies, including Alzheimer's disease, PSP, and FTD; and VY-NAV01 for severe chronic pain. The company has strategic collaboration agreement with AbbVie Inc.; Sanofi Genzyme; the University of Massachusetts; and MRI Interventions, Inc., as well as has collaborations with Brammer Bio and Fujifilm Diosynth Biotechnologies to support the development of its gene therapy programs. It also has a collaboration and license agreement with Neurocrine Biosciences, Inc. for the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. Receive VYGR News and Ratings via Email Sign-up to receive the latest news and ratings for VYGR and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VYGR Previous Symbol CUSIPN/A CIK1640266 Webwww.voyagertherapeutics.com Phone857-259-5340Debt Debt-to-Equity RatioN/A Current Ratio6.08 Quick Ratio6.08Price-To-Earnings Trailing P/E Ratio-4.05 Forward P/E Ratio-3.91 P/E GrowthN/A Sales & Book Value Annual Sales$10.14 million Price / Sales34.29 Cash FlowN/A Price / Cash FlowN/A Book Value$4.26 per share Price / Book2.51Profitability EPS (Most Recent Fiscal Year)($2.64) Net Income$-70,690,000.00 Net Margins-648.40% Return on Equity-81.63% Return on Assets-37.31%Miscellaneous Employees88 Outstanding Shares32,560,000Market Cap$347.74 million Next Earnings Date2/26/2019 (Confirmed) OptionableOptionable Voyager Therapeutics (NASDAQ:VYGR) Frequently Asked Questions What is Voyager Therapeutics' stock symbol? Voyager Therapeutics trades on the NASDAQ under the ticker symbol "VYGR." How were Voyager Therapeutics' earnings last quarter? Voyager Therapeutics Inc (NASDAQ:VYGR) posted its quarterly earnings results on Tuesday, August, 7th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.67) by $0.13. The business had revenue of $2.58 million for the quarter, compared to analyst estimates of $3 million. Voyager Therapeutics had a negative net margin of 648.40% and a negative return on equity of 81.63%. View Voyager Therapeutics' Earnings History. When is Voyager Therapeutics' next earnings date? Voyager Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for Voyager Therapeutics. What price target have analysts set for VYGR? 8 analysts have issued twelve-month price objectives for Voyager Therapeutics' stock. Their predictions range from $13.00 to $40.00. On average, they anticipate Voyager Therapeutics' stock price to reach $26.6250 in the next year. This suggests a possible upside of 149.3% from the stock's current price. View Analyst Price Targets for Voyager Therapeutics. What is the consensus analysts' recommendation for Voyager Therapeutics? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Voyager Therapeutics in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Voyager Therapeutics. What are Wall Street analysts saying about Voyager Therapeutics stock? Here are some recent quotes from research analysts about Voyager Therapeutics stock: 1. According to Zacks Investment Research, "Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (2/9/2019) 2. HC Wainwright analysts commented, "Our $21 price target is based on a 13-year DCF analysis leveraged solely to the prospects of VY- AADC in PD, which potentially leaves significant upside if the remainder of the pipeline matures favorably. Our DCF analysis is based on: beta of 1.47, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.0%, and tax rate of 15% beginning in FY 2027." (1/15/2019) 3. BTIG Research analysts commented, "Before mkt open on Thursday, Voyager released their 1Q18 financial results and update. Management reconfirmed that the first patient in the Phase 2-3 Parkinson’s (PD) studies could be dosed during mid-2018, and further confirmed that posterior delivery will be the preferred approach. The decision to use posterior delivery was based upon improved safety, surgical time, and coverage of the putamen – with first data from the posterior study being presented later in 2Q18. The posterior study dataset will focus on patients with 6-months of follow-up, which will be a small group of patients, as the 8 th patient in the posterior study was recently dosed. We reiterate our Buy rating and $32 PT as we remain positive on the PD effort." (5/13/2018) Has Voyager Therapeutics been receiving favorable news coverage? Media stories about VYGR stock have been trending positive recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Voyager Therapeutics earned a coverage optimism score of 2.3 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 8.0 out of 10, meaning that recent news coverage is very likely to have an impact on the stock's share price in the next several days. Who are some of Voyager Therapeutics' key competitors? Some companies that are related to Voyager Therapeutics include Orchard Therapeutics (ORTX), Momenta Pharmaceuticals (MNTA), Iovance Biotherapeutics (IOVA), Autolus Therapeutics (AUTL), Audentes Therapeutics (BOLD), Rubius Therapeutics (RUBY), Coherus Biosciences (CHRS), BioCryst Pharmaceuticals (BCRX), Editas Medicine (EDIT), Fate Therapeutics (FATE), Sangamo Therapeutics (SGMO), Vericel (VCEL), Novavax (NVAX), BAVARIAN NORDIC/S (BVNRY) and Heska (HSKA). What other stocks do shareholders of Voyager Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Voyager Therapeutics investors own include TherapeuticsMD (TXMD), SCYNEXIS (SCYX), Micron Technology (MU), Sangamo Therapeutics (SGMO), Cara Therapeutics (CARA), Crispr Therapeutics (CRSP), Amicus Therapeutics (FOLD), Progenics Pharmaceuticals (PGNX), bluebird bio (BLUE) and Editas Medicine (EDIT). Who are Voyager Therapeutics' key executives? Voyager Therapeutics' management team includes the folowing people: Mr. Matthew P. Ottmer, Chief Operating Officer (Age 48)Dr. Steven M. Paul, Exec. Science Advisor & Director (Age 68)Mr. G. Andre Turenne, CEO, Pres & DirectorDr. Krystof Bankiewicz M.D., Ph.D., FounderDr. Guangping Gao Ph.D., Founder Who are Voyager Therapeutics' major shareholders? Voyager Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BB Biotech AG (8.80%), BlackRock Inc. (5.71%), Casdin Capital LLC (3.46%), Millennium Management LLC (1.26%), Great Point Partners LLC (1.12%) and Geode Capital Management LLC (0.88%). Company insiders that own Voyager Therapeutics stock include Bernard Ravina, Dinah PhD Sah, Glenn Pierce, James A Geraghty and Jane Henderson. View Institutional Ownership Trends for Voyager Therapeutics. Which major investors are selling Voyager Therapeutics stock? VYGR stock was sold by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Millennium Management LLC, Tocqueville Asset Management L.P., Bellevue Group AG, Northern Trust Corp, MetLife Investment Advisors LLC, Casdin Capital LLC and Oppenheimer & Co. Inc.. Company insiders that have sold Voyager Therapeutics company stock in the last year include Bernard Ravina, Dinah PhD Sah and Jane Henderson. View Insider Buying and Selling for Voyager Therapeutics. Which major investors are buying Voyager Therapeutics stock? VYGR stock was purchased by a variety of institutional investors in the last quarter, including Citigroup Inc., Two Sigma Investments LP, Geode Capital Management LLC, SG Americas Securities LLC, Acadian Asset Management LLC, BB Biotech AG, D. E. Shaw & Co. Inc. and GSA Capital Partners LLP. Company insiders that have bought Voyager Therapeutics stock in the last two years include Glenn Pierce and James A Geraghty. View Insider Buying and Selling for Voyager Therapeutics. How do I buy shares of Voyager Therapeutics? Shares of VYGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Voyager Therapeutics' stock price today? One share of VYGR stock can currently be purchased for approximately $10.68. How big of a company is Voyager Therapeutics? Voyager Therapeutics has a market capitalization of $347.74 million and generates $10.14 million in revenue each year. The company earns $-70,690,000.00 in net income (profit) each year or ($2.64) on an earnings per share basis. Voyager Therapeutics employs 88 workers across the globe. What is Voyager Therapeutics' official website? The official website for Voyager Therapeutics is http://www.voyagertherapeutics.com. How can I contact Voyager Therapeutics? Voyager Therapeutics' mailing address is 75 SIDNEY STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-5340 or via email at [email protected] MarketBeat Community Rating for Voyager Therapeutics (NASDAQ VYGR)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 262 (Vote Outperform)Underperform Votes: 212 (Vote Underperform)Total Votes: 474MarketBeat's community ratings are surveys of what our community members think about Voyager Therapeutics and other stocks. Vote "Outperform" if you believe VYGR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VYGR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/22/2019 by MarketBeat.com StaffFeatured Article: Are analyst ratings accurate?